Filtros

Buscador
Año
Lopez-Galvez R, Rivera-Caravaca JM, Anguita Sanchez M, Sanmartin Fernandez M, Rafols C, Perez-Cabeza AI, Baron Esquivias G, Lekuona Goya I, Vazquez Rodriguez JM, Cosin Sales J, Arribas Ynsaurriaga F, Barrios V, Freixa-Pamias R, Marin F. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. Eur J Clin Invest. 2022 Sep;52(9):e13788. doi: 10.1111/eci.13788. Epub 2022 Apr 14. PubMed PMID: 35395094.
AÑO: 2022; IF: 5.5
Lopez-Galvez R, Marin F, Rivera-Caravaca JM. Predicting heart failure in atrial fibrillation patients: What about using biomarkers? Am Heart J. 2022 Sep;251:32-34. doi: 10.1016/j.ahj.2022.05.007. Epub 2022 May 7. No abstract available. PubMed PMID: 35537504.
AÑO: 2022; IF: 4.8
Esteve-Pastor MA, Rivera-Caravaca JM, Ruiz-Ortiz M, Muniz J, Roldan-Rabadan I, Otero D, Lopez-Galvez R, Cequier A, Bertomeu-Martinez V, Badimon L, Anguita M, Lip GYH, Marin F; FANTASIIA investigators. A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry. Expert Opin Pharmacother. 2022 Aug;23(12):1457-1465. doi: 10.1080/14656566.2022.2109961. Epub 2022 Aug 12. PubMed PMID: 35924672.
AÑO: 2022; IF: 3.2
Lopez-Galvez R, Rivera-Caravaca JM. Growth Differentiation Factor 15 in Cardiovascular Diseases: Predicting Bleeding after Cardiac Surgery and Beyond That! Thromb Haemost. 2022 May;122(5):657-660. doi: 10.1055/a-1768-4206. Epub 2022 May 5. No abstract available. PubMed PMID: 35144304.
AÑO: 2022; IF: 6.7
Lopez-Galvez R, de la Morena-Barrio ME, Minano A, Pathak M, Marcos C, Emsley J, Caballero T, Lopez-Trascasa M, Vicente V, Corral J, Lopez-Lera A. Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 P.Thr309Lys Variant. Clin Rev Allergy Immunol. 2021 Jun;60(3):357-368. doi: 10.1007/s12016-021-08840-x. Epub 2021 Mar 16. PubMed PMID: 33725261.
AÑO: 2021; IF: 10.817